- |||||||||| Trileptal (oxcarbazepine) / Novartis
Journal: Modern aspects of antiepileptic therapy during pregnancy (Pubmed Central) - Jun 15, 2019
In addition to classic AEDs, new AEDs (vigabatrin, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin) were investigated...It has been found that the risk of birth defects in children is associated with high doses of drugs and polytherapy compared to monotherapy. New data of recent studies showed the effect of psychotropic drugs on the fetus allowing to assess the 'risk/benefit' ratio and develop recommendations on rational pharmacotherapy of epilepsy in pregnancy.
- |||||||||| pregabalin / generics, carbamazepine / generics
Journal, Adverse events: Level of physicians' awareness of antiepileptic drug adverse effects. (Pubmed Central) - Jun 15, 2019
Majority of the adverse effects were not documented in the patients' files. However, physicians were aware of majority of the adverse effects associated with AEDs.
- |||||||||| levetiracetam / generics
Journal: Therapeutic levetiracetam monitoring during pregnancy: "mind the gap". (Pubmed Central) - Jun 14, 2019
Monitoring of LEV serum levels is essential upon planning pregnancy and thereafter if pre-pregnancy LEV levels are to be maintained. However, more studies are needed to assess the correlation with clinical outcome.
- |||||||||| levetiracetam / generics
Clinical, Journal: Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients. (Pubmed Central) - Jun 7, 2019
There is a trend of lower rates of seizure freedom in patients treated with LEV than in those treated with VPA after the first-year treatment period. Our data suggest that in JME, seizure control is linked to seizure type, possibly allowing a more individualized approach when counseling JME patients.
- |||||||||| Brabafen (low-dose fenfluramine) / Zogenix
Review, Journal: Treatment Strategies for Dravet Syndrome. (Pubmed Central) - May 31, 2019
Status epilepticus is a recurring problem for patients with DS, particularly in their early childhood years. All patients should be prescribed a home rescue therapy (usually a benzodiazepine) but should also have a written seizure action plan that outlines when rescue should be given and further steps to take in the local hospital if the seizure persists despite home rescue therapy.
- |||||||||| carbamazepine / generics
Journal: The Outcome of Status Epilepticus and Long-Term Follow-Up. (Pubmed Central) - May 21, 2019
The worst outcome was linked to advanced age, etiology, new onset status epilepticus, NCSE, and focal status epilepsy. This study highlights the importance of regular care and patient follow-up.
- |||||||||| levetiracetam / generics
Review, Journal: Poststroke seizure: optimising its management. (Pubmed Central) - May 21, 2019
Levetiracetam and lamotrigine are the most studied newer generation AEDs and have the best drug tolerance. The purpose of this review is to summarise the recent advances in PSS research and focus on the most important practice issues of PSS management.
- |||||||||| Trial completion date, Trial primary completion date: PADRE: Pharmacokinetics of Antiepileptics in Patients on CRRT (clinicaltrials.gov) - May 20, 2019
P4, N=30, Recruiting,
The purpose of this review is to summarise the recent advances in PSS research and focus on the most important practice issues of PSS management. Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||||||||| levetiracetam / generics
Clinical, Journal: Comorbidity of migraine and epilepsy in childhood (Pubmed Central) - May 18, 2019
The efficacy of antiepileptic drugs has been proven as the prophylactic treatment of migraine in pediatric patients. The advantages of levetiracetam as the prophylactic treatment for migraine and epilepsy comorbidity in children are discussed.
- |||||||||| levetiracetam / generics
Journal: Drug-drug interactions between antiepileptics and cannabinoids. (Pubmed Central) - May 16, 2019
Cannabidiol proved effective in clinical trials, reducing seizure frequency and the most frequently observed adverse effects were diarrhea, somnolence, and poor appetite. The retention rate was within 14-24% (12-14 weeks - 1 year) but it reached the level of 35% after 2 years.
- |||||||||| Preclinical, Journal: The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats. (Pubmed Central) - May 15, 2019
Further, our results demonstrate for the first time that these effects are more pronounced in ovariectomised rats as compared to normal rats and that this could be related to estrogen deficiency which in turn enhances bone resorption via increased RANKL and reduces bone formation via increased sclerostin and reduced P1NP. Finally, our study demonstrated for the first time that AED treatment displayed changes in the serum levels of wnt inhibitors and hence modulation of wnt inhibitors might be partly involved in their adverse effects on bone.
- |||||||||| Trileptal (oxcarbazepine) / Novartis
Journal: Reliability of information about the use of antiepileptic drugs during pregnancy from three major web search engines in China. (Pubmed Central) - May 14, 2019
Finally, our study demonstrated for the first time that AED treatment displayed changes in the serum levels of wnt inhibitors and hence modulation of wnt inhibitors might be partly involved in their adverse effects on bone. Accurate and professional online information for female patients with epilepsy should be provided through major efforts by the government, search engine companies, professional websites and epilepsy physicians.
- |||||||||| Seizalam (midazolam intramuscular) / Pfizer
Review, Journal: Focal status epilepticus: a review of pharmacological treatment. (Pubmed Central) - May 12, 2019
The available scientific evidence is insufficient to claim that pharmacological treatment of focal SE should be different from treatment for generalised SE. More studies with a greater number of patients are needed.
- |||||||||| carbamazepine / generics
Clinical, Review, Journal: Strategies of using the new antiepileptic drugs for epilepsy in adults (Pubmed Central) - May 11, 2019
The new antiepileptic drugs can succesfully used for the treatment of special patients' groups as for the post stroke, poszttraumatic epilepsies, for the epilepsies accompanied with brain tumours as well as for epilepsies in the elderly. The new drugs are advantageous for the treatment of such patients who have psychiatric symptoms or signs of cognitive decline and high risk of these symptoms respectively.
- |||||||||| Briviact (brivaracetam) / UCB
Retrospective data, Journal: BRIVA-LIFE - a multicentre retrospective study of the long-term use of brivaracetam in clinical practice. (Pubmed Central) - May 9, 2019
The new drugs are advantageous for the treatment of such patients who have psychiatric symptoms or signs of cognitive decline and high risk of these symptoms respectively. In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.
- |||||||||| Cerebyx (fosphenytoin) / Pfizer, Nobelpharma
Journal: Levetiracetam in toxic seizures. (Pubmed Central) - May 7, 2019
Levetiracetam used as a second-line agent was associated with control of drug-induced seizures and prevention of seizure recurrence without obvious adverse effects. A prospective study is needed to confirm these results.
- |||||||||| pentylenetetrazole (BTD-001) / Balance Therap
Journal: Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy (Pubmed Central) - May 7, 2019
In addition, the Sv2a mutation specifically impaired depolarization-induced GABA, but not glutamate, release in the hippocampus and amygdala. All this evidence indicates that the SV2A-GABAergic system plays a crucial role in modulating epileptogenesis and encourages discovery research into the novel antiepileptic agents which enhance the function of the SV2A-GABA system.
- |||||||||| pregabalin / generics
Clinical, Journal: Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus. (Pubmed Central) - May 7, 2019
We propose a treatment protocol based on a sequential combination of anaesthetics, anti-epileptic drugs and alternative therapies. Strategies to evaluate treatment response and to wean drugs based on clinical results are also proposed.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe
Clinical, Journal: Atypical case of posterior reversible encephalopathy syndrome related to late onset postpartum eclampsia: A case report. (Pubmed Central) - May 5, 2019
Her clinical course was uneventful and she fully recovered without neurological complications LESSONS:: The possible diagnosis of late onset postpartum eclampsia, even weeks post-delivery, should be considered, since initiation of early treatment averts severe complications and decreases mortality. Sharing our experience may increase awareness of PRES induced by late-onset postpartum eclampsia.
- |||||||||| levetiracetam / generics
Retrospective data, Review, Journal: A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy. (Pubmed Central) - May 4, 2019
Regarding safety profile, patients treated with levetiracetam had significantly higher occurrence than placebo for somnolence, asthenia, dizziness, infection, nasopharyngitis, anxiety, and irritability; however, most studies reported that these adverse events were mild and transient. Levetiracetam is an effective anti-epileptic drug for both adults and children with generalized or partial-onset refractory seizures at 1,000-3,000 or 60 mg/kg/day, with a favorable adverse event profile.
- |||||||||| levetiracetam / Generic mfg.
Enrollment closed, Phase classification: Levetiracetam Treatment of Neonatal Seizures (clinicaltrials.gov) - May 1, 2019
P1/2, N=100, Active, not recruiting,
SPFL risk is increased in pregnancies with AED exposure, being least with levetiracetam and highest with topiramate. Recruiting --> Active, not recruiting | Phase classification: P4 --> P1/2
- |||||||||| Trileptal (oxcarbazepine) / Novartis
Journal: Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. (Pubmed Central) - Apr 30, 2019
For the older first generation AEDs (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone and valproic acid), much data has accumulated in this regard. However, this is occurring increasingly for the new AEDs (brivaracetam, eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, piracetam, pregabalin, rufinamide, stiripentol, sulthiame, tiagabine, topiramate, vigabatrin and zonisamide).
- |||||||||| levetiracetam / generics
PK/PD data, Journal: Influence of Sex, Age and Weight on Levetiracetam Pharmacokinetics. (Pubmed Central) - Apr 30, 2019
It is confirmed that LEV dosage per body weight is not required, and prescribing higher doses of LEV in obese patients is not justified. These data suggest that routine LEV therapeutic drug monitoring (TDM) in the elderly patients, patients with renal dysfunction and obese patients is indicated.
- |||||||||| levetiracetam / generics
Clinical, Journal: Diagnostics and treatment of children with acute seizures on paediatric intensive care unit. (Pubmed Central) - Apr 28, 2019
Midazolam was the first lime anticonvulsive medication used in most of the children, while phenobarbital, levetiracetam or phenytoin were the preferred second line drugs. Keywords: acute seizures, asymmetric clonic seizure, febrile seizure, children, paediatric intensive care unit.
- |||||||||| levetiracetam / generics
Journal: On-demand manufacturing of immediate release levetiracetam tablets using pressure-assisted microsyringe printing. (Pubmed Central) - Apr 24, 2019
Tablets with PVA-PEG disintegrated within 95 ± 10 s while tablets with additional PVP-PVAc disintegrated witin 130 ± 20 s. Friability of < 0.5 % indicate that the used PAM printing method provides tablets without loss of structural integrity during handling. Furthermore, it could be shown that the production of tablets with a good content uniformity using a 3D Bioplotter is suitable.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Apr 20, 2019
P2, N=43, Terminated,
Furthermore, it could be shown that the production of tablets with a good content uniformity using a 3D Bioplotter is suitable. Completed --> Terminated; Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible.
|
